ОСОБЕННОСТИ НОВОГО ИНГИБИТОРА ПРОТОННОЙ ПОМПЫ ДЕКСЛАНСОПРАЗОЛА В КАПСУЛАХ С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ (ДЕКСИЛАНТ®)*

Скачать статью в PDF
Номер журнала: 
1
Год издания: 
2015

М. Осипенко, доктор медицинских наук, профессор, С. Холин, кандидат медицинских наук Новосибирский государственный медицинский университет E-mail: ngma@bk.ru

В статье дан современный обзор особенностей фармакокинетики нового инновационного ингибитора протонной помпы (ИПП) – капсул с модифицированным высвобождением декслансопразола (Дексилант®). Благодаря двухэтапному высвобождению и увеличению времени нахождения препарата в крови препарат показал высокую эффективность в лечении различных форм гастроэзофагеальной рефлюксной болезни, по ряду показателей превосходящую эффективность других ИПП, а также обеспечивающую бóльшую приверженность больных лечению.
Ключевые слова: 
гастроэзофагеальная рефлюксная болезнь
ингибиторы протонной помпы
Дексилант®
Для цитирования
Осипенко М., Холин С. ОСОБЕННОСТИ НОВОГО ИНГИБИТОРА ПРОТОННОЙ ПОМПЫ ДЕКСЛАНСОПРАЗОЛА В КАПСУЛАХ С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ (ДЕКСИЛАНТ®)* . Врач, 2015; (1): 25-29

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Sachs G., Shin J., Howden C. Review article: the clinical pharmacology of proton pump inhibitors // Aliment. Pharmacol. Ther. – 2006; 23 (suppl. 2): 2–8.
  2. Metz D., Ferron G., Paul J. et al. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study // J. Clin. Pharmacol. – 2002; 42: 512–9.
  3. Sachs G., Shin J., Vagin O. et al. The Gastric H, K ATPase of a Drug Target: past, present, and future // J. Clin. Gastroenterol. – 2007; 41 (Suppl. 2): 226–42.
  4. Dent J., Brun J., Fendrick A. et al. An evidence-based appraisal of reflux disease management-the Geneva Workshop report // Gut. – 1999; 44 (Suppl. 2): 1–16.
  5. DeVault K., Castell D. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease // Am. J. Gastroenterol. – 2005; 100: 190–200.
  6. Chey W., Inadomi J., Booher A. et al. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey // Am. J. Gastroenterol. – 2005; 100: 1237–42.
  7. Tonini M., DeGiorgio R., DePonti F. Novel therapeutic strategies in acid-7. related disorders // Exp. Opin. Ther. Patents. – 2003; 13: 639–49.
  8. Hunt R. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005 // Aliment. Pharmacol. Ther. – 2005; 22 (Suppl. 3): 10–9.
  9. Bate C., Booth S., Crowe J. et al. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? // Aliment. Pharmacol. Ther. – 1993; 7: 501–7.
  10. Claxton A., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance // Clin. Ther. – 2001; 23: 1296–310.
  11. Miner P., Katz P., Chen Y. et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study // Am. J. Gastroenterol. – 2003; 98: 2616–20.
  12. Behm B., Peura D. Dexlansoprazole MR for the management of gastroesophageal reflux disease // Expert Rev. Gastroenterol. Hepatol. – 2011; 5: 439–45.
  13. Vakily M. et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials // Curr. Med. Res. Opin. – 2009; 25: 627–38.
  14. Metz D., Vakily M., Dixit T. et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy // Aliment. Pharmacol. Ther. – 2009; 29: 928–37.
  15. Chey W., Inadomi J., Booher A. et al. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey // Am. J. Gastroenterol. – 2005; 100: 1237–42.
  16. Persson K. When do ulcer patients take their acid inhibiting medication? // Hassle Information. – 1993; 7: 19–23
  17. Solem C., Mody R., Stephens J. et al. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: Physician knowledge, patient adherence // J. Am. Pharm. Assoc. – 2014; 54: 144–53.
  18. Nexium (esomeprazole magnesium). Full Prescribing Information. Wilmington, DE: AstraZeneca LP, 2008.
  19. Sostek M., Chen Y., Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole // Br. J. Clin. Pharmacol. – 2007; 64: 386–90.
  20. Vaz-da-Silva M., Loureiro A., Nunes T. et al. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions // Clin. Drug. Investig. – 2005; 25: 391–9.
  21. Bergstrand R., Grind M., Nyberg G. et al. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standard breakfast // Clin. Drug. Invest. – 1995; 9: 67–71.
  22. Lee R., Vakily M., Mulford D. et al. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor – evidence for dosing flexibility // Aliment. Pharmacol. Ther. – 2009; 29: 824–33.
  23. Lee R., Mulford D., Wu J. et al. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor // Aliment. Pharmacol. Ther. – 2010; 31: 1001–11.
  24. Nexium (esomeprazole magnesium) Full Prescribing Information. Wilmington, DE: AstraZeneca LP, 2008.
  25. Prilosec (Omeprazole). Full Prescribing Information. Wilmington, DE: 25. AstraZeneca LP, 2008.
  26. Prevacid (lansoprazole). Full Prescribing Information. Deerfield, IL: Takeda 26. Pharmaceuticals America, Inc., 2009.
  27. Lee R., Mulford D., Wu J. et al. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor // Aliment. Pharmacol. Ther. – 2010; 31: 1001–11
  28. Kapidex (dexlansoprazole). Full Prescribing Information. Deerfield, IL: 28. Takeda Pharmaceuticals America, Inc., 2009
  29. Kukulka M., Eisenberg C., Nudurupati S. Comparator pH study to evaluate 29. the singledose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg // Clin. Exp. Gastroenterol. – 2011; 4: 213–20.
  30. Nojkov B., Rubenstein J., Adlis S. et al. The influence of co-morbid IBS and 30. psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease // Aliment. Pharmacol. Ther. – 2008; 27: 473–82.
  31. Nocon M., Labenz J., Jaspersen D. et al. Long-term treatment of patients 31. with gastro-oesophageal reflux disease in routine care – results from the ProGERD study // Aliment. Pharmacol. Ther. – 2007; 25: 715–22.
  32. Sharma P., Shaheen N., Perez M. et al. Clinical trials: healing of erosive 32. oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation – results from two randomized controlled studies // Aliment. Pharmacol. Ther. – 2008; 29: 731–41
  33. Donnellan C., Sharma N., Preston C. et al. Medical treatments for the 33. maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease // Cochrane Database Syst. Rev. – 2004: CD003245.
  34. Metz D., Howden C., Perez M. et al. Clinical trial: dexlansoprazole MR, a 34. proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis // Aliment. Pharmacol. Ther. – 2009; 29: 742–54.
  35. Fass R. Proton pump inhibitor failure–what are the therapeutic options? // 35. Am. J. Gastroenterol. – 2009; 104 (Suppl. 2): 33–8.
  36. Kahrilas P., Shaheen N., Vaezi M. et al. American Gastroenterological 36. Association medical position statement on the management of gastroesophageal reflux disease // Gastroenterology. – 2008; 135: 1383–91.
  37. Chey W., Mody R., Wu E. et al. Treatment patterns and symptom control in 37. patients with GERD: US community-based survey // Curr. Med. Res. Opin. – 2009; 25: 1869–78.
  38. Heidelbaugh J., Goldberg K., Inadomi J. Overutilization of proton pump 38. inhibitors: a review of cost-effectiveness and risk [corrected] // Am. J. Gastroenterol. – 2009; 104 (Suppl. 2): 27–32.
  39. Fass R., Inadomi J., Han C. et al. Maintenance of Heartburn Relief After 39. Step-Down From Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole Modified Release // Clin. gastroenterol. hepatol. – 2012; 10: 247–53.
  40. Dean B., Gano A.-Jr., Knight K. et al. Effectiveness of proton pump 40. inhibitors in nonerosive reflux disease // Clin. Gastroenterol. Hepatol. – 2004; 2: 656–64.
  41. Fass R., Chey W., Zakko S. et al. Clinical trial: the effects of the proton 41. pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease // Aliment. Pharmacol. Ther. – 2009; 29: 1261–72.
  42. Mody R., Bolge S., Kannan H. et al. Effects of gastroesophageal refl ux 42. disease on sleep and outcomes // Clin. Gastroenterol. Hepatol. – 2009; 7: 953–9.
  43. Fass R., Johnson D., Orr W. et al. The Effect of Dexlansoprazole MR on 43. Nocturnal Heartburn and GERD-Related Sleep Disturbances in Patients With Symptomatic GERD // Am. J. Gastroenterol. – 2011; 106: 421–31.